{"entity":{"id":"rvu120","kind":"drug","name":"RVU120","aka":["SEL120"],"tldr":"RVU120 is a small-molecule inhibitor from Ryvu Therapeutics SA, in registered phase 2 trials for acute myeloid leukaemia.","summary":"RVU120 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Ryvu Therapeutics SA, in acute myeloid leukaemia. Described in the registry record as a selective inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-2","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of RVU120","url":"https://clinicaltrials.gov/search?intr=RVU120"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["ryvu-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06191263"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"code":"RVU120","modality":"Small-molecule inhibitor","mechanism":"Described in the registry record as a selective inhibitor; the trial entries below carry the sponsor's wording.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/rvu120/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"company":[{"id":"ryvu-therapeutics","kind":"company","name":"Ryvu Therapeutics","route":"/companies/ryvu-therapeutics/"}],"trial":[{"id":"nct06191263","kind":"trial","name":"Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML","route":"/trials/nct06191263/"}]}}